Fresenius Medical Care AG (ETR:FME)
Germany
· Delayed Price · Currency is EUR | Market Cap | 13.87B |
| Revenue (ttm) | 19.49B |
| Net Income (ttm) | 618.18M |
| Shares Out | 293.41M |
| EPS (ttm) | 2.11 |
| PE Ratio | 22.44 |
| Forward PE | 12.62 |
| Dividend | 1.44 (2.91%) |
| Ex-Dividend Date | May 23, 2025 |
| Volume | 1,054,992 |
| Average Volume | 555,799 |
| Open | 49.05 |
| Previous Close | 49.49 |
| Day's Range | 46.72 - 49.72 |
| 52-Week Range | 32.51 - 54.02 |
| Beta | 0.85 |
| RSI | 36.35 |
| Earnings Date | Aug 5, 2025 |
About Fresenius Medical Care AG
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient’s residence; and dialysis services under contract to hospitals in the United States for the hospital... [Read more]
Financial Performance
In 2024, Fresenius Medical Care AG's revenue was 19.34 billion, a decrease of -0.61% compared to the previous year's 19.45 billion. Earnings were 537.91 million, an increase of 7.80%.
Financial StatementsNews
Fresenius Medical Care initiates €1B share buyback
Fresenius Medical Care Launches Value-Based Care Segment, Eyes Growth Through Innovation, Efficiency
Fresenius Medical Care AG (NYSE: FMS) on Tuesday introduced a strategic roadmap — FME Reignite — aimed at revitalizing its core business, driving innovation and reshaping its organizational culture. ...
Fresenius Medical Care Launches Value-Based Care Segment, Eyes Growth Through Innovation, Efficiency
Fresenius Medical Care AG FMS on Tuesday introduced a strategic roadmap — FME Reignite — aimed at revitalizing its core business, driving innovation and reshaping its organizational culture.
Fresenius Medical Care CEO Says Company Could Benefit From Obesity Drugs
EXCLUSIVE: The dialysis company believes the impact of the treatments on its own performance will be ‘neutral to positive' rather than negative.
Fresenius Medical Care Launches its Strategy FME Reignite with increased Profitability Aspirations, and a New Capital Allocation Framework to further enhance Value Creation
FME Reignite sets the ambition to lead kidney care through exceptional patient care and innovation The Company will set the new standard of care in the U.S. with the introduction of the 5008X dialysis...
Fresenius Medical Care announces 1 bln euros share buyback programme
The world's largest dialysis specialist Fresenius Medical Care said, ahead of its capital markets day on Tuesday, that it plans to embark on a 1 billion euros ($1.16 billion) share buyback programme.
EQS-Adhoc: Fresenius Medical Care AG : Fresenius Medical Care AG resolves share buyback program with a total volume of EUR 1 billion in tranches within 2 years
EQS-Ad-hoc: Fresenius Medical Care AG / Key word(s): Share Buyback Fresenius Medical Care AG : Fresenius Medical Care AG resolves share buyback program with a total volume of EUR 1 billion in tranches...
5 Stocks To Ride The German Market Rally
Stocks in the United States have struggled to regain their February all-time highs amid the tariff uncertainty. In fact, the S&P 500 remains one of the worst-performing major stock indices in the deve...
Fresenius Medical Care Begins Broader U.S. Commercialization of 5008X™ CAREsystem, Achieves Key Milestones in Efforts to Introduce High-Volume Hemodiafiltration Dialysis Therapy to Individuals with Kidney Disease in the U.S.
Updated 5008X CAREsystem with Additional Features Receives FDA 510(k) Clearance Company announces first wave of Fresenius Kidney Care clinics in the U.S. to begin offering high-volume hemodiafiltrati...
Fresenius Medical Care presents its new research and innovation for kidney care at European Renal Association Congress 2025
Key abstract presentations showcase significant advancements in clinical care, artificial intelligence, and fluid management, demonstrating Fresenius Medical Care's commitment to improving patient out...
EQS-PVR: Fresenius Medical Care AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Fresenius Medical Care AG Fresenius Medical Care AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Eu...
Fresenius Medical Care Annual General Meeting: Strong Performance Against Its Strategic Plan Results in Highest Dividend per Share in Its History
Shareholders approved the proposed dividend of 1.44 Euro per share, representing a 21 percent increase year-over-year and marking the highest dividend in the company's history Excellent progress in th...
Fresenius Medical Care AG 2025 Q1 - Results - Earnings Call Presentation
Fresenius Medical Care AG (FMS) Q1 2025 Earnings Conference Call Transcript
EQS-CMS: Fresenius Medical Care AG : Release according to Article 50 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Post-admission Duties announcement: Fresenius Medical Care AG / Third country release according to Article 50 Para. 1, No. 2 of the WpHG [the German Securities Trading Act] Fresenius Medical Care ...
Fresenius Medical Care Non-GAAP EPS of €0.84, revenue of €4.88B; reaffirms FY25 outlook
Fresenius Medical Care starts 2025 with strong organic revenue and income growth
Strong organic revenue growth1 of 5% driven by Care Enablement and Care Delivery Stable U.S. same market treatment development despite impact from a severe flu season FME25 savings of EUR 68 million c...
Fresenius Medical Care tops market expectations in 1st quarter
World's largest dialysis specialist Fresenius Medical Care reported first-quarter results above analysts' expectations on Tuesday, as revenue grew organically in all its segments, it said.
Fresenius Medical Care: Why I'm Not (Yet) Biting Despite Turnaround Progress
Investigating Privia Health Gr's Standing In Health Care Providers & Services Industry Compared To Competitors
In the dynamic and fiercely competitive business environment, conducting a thorough analysis of companies is crucial for investors and industry enthusiasts. In this article, we will perform an extensi...
EQS-PVR: Fresenius Medical Care AG: Correction of a release from 10/04/2025 according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Fresenius Medical Care AG Fresenius Medical Care AG: Correction of a release from 10/04/2025 according to Article 40, Section 1 of the WpHG [the German Securities Tradi...
BMO's Siegerman talks the impact of tariffs on pharmaceutical stocks
Evan Seigerman, BMO, joins 'Fast Money' to talk the impact of tariffs on pharma space.
EQS-PVR: Fresenius Medical Care AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Fresenius Medical Care AG Fresenius Medical Care AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Eu...
EQS-DD: Fresenius Medical Care AG: Dr. Katarzyna Mazur-Hofsäß, Acquisition of shares under the Fresenius Medical Care Management Board Long Term Incentive Plan 2020 (Allocation 2022)
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 19.03.2025 / 09:50 CET/CEST The issuer is solely responsi...
EQS-DD: Fresenius Medical Care AG: Franklin W. Maddux, Acquisition of shares under the Fresenius Medical Care Management Board Long Term Incentive Plan 2020 (Allocation 2022)
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 19.03.2025 / 09:48 CET/CEST The issuer is solely responsi...